Thomas J. Ettrich
About
Thomas J. Ettrich is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Thomas J. Ettrich has authored 146 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Oncology, 73 papers in Pulmonary and Respiratory Medicine and 45 papers in Surgery. Recurrent topics in Thomas J. Ettrich's work include Gastric Cancer Management and Outcomes (49 papers), Pancreatic and Hepatic Oncology Research (46 papers) and Colorectal Cancer Treatments and Studies (41 papers). Thomas J. Ettrich is often cited by papers focused on Gastric Cancer Management and Outcomes (49 papers), Pancreatic and Hepatic Oncology Research (46 papers) and Colorectal Cancer Treatments and Studies (41 papers). Thomas J. Ettrich collaborates with scholars based in Germany, United States and Switzerland. Thomas J. Ettrich's co-authors include Thomas Seufferlein, Lukas Perkhofer, Andreas W. Berger, Peter Thuss‐Patience, Sylvie Lorenzen, Alexander Kleger, Eray Goekkurt, Stefan Schmidt, Ralf Marienfeld and Michael Geißler and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and PLoS ONE.
In The Last Decade
Thomas J. Ettrich
128 papers receiving 1.8k citations
Peers
Thomas J. Ettrich
Mitsukuni Suenaga Japan
Roger Faroux France
Petra Ruemmele Germany
Tsuyoshi Hayashi Japan
Nobuhisa Matsuhashi Japan
Kazuhito Sasaki Japan
Yu Sunakawa Japan
Yasuo Ohkura Japan
Chueh‐Chuan Yen Taiwan
Kuk Jin Choe South Korea
Citations per year, relative to Thomas J. Ettrich Thomas J. Ettrich (= 1×)
peers
Mitsukuni Suenaga
Countries citing papers authored by Thomas J. Ettrich
Since
Specialization
Citations
This map shows the geographic impact of Thomas J. Ettrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Ettrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Ettrich more than expected).
Fields of papers citing papers by Thomas J. Ettrich
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Thomas J. Ettrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Ettrich. The network helps show where Thomas J. Ettrich may publish in the future.
Co-authorship network of co-authors of Thomas J. Ettrich
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas J. Ettrich. A scholar is included among the top collaborators of Thomas J. Ettrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas J. Ettrich. Thomas J. Ettrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Berger, Moritz, Farsaneh Sadeghlar, Christoph Roderburg, et al.. (2024). 191P Evaluating sorafenib as second-line treatment for advanced hepatocellular carcinoma: SORA-2, an European retrospective multicenter study. Annals of Oncology. 35. S86–S86.
2.
Wolf, Daniel, et al.. (2024). Applicability of the CT Radiomics of Skeletal Muscle and Machine Learning for the Detection of Sarcopenia and Prognostic Assessment of Disease Progression in Patients with Gastric and Esophageal Tumors. Diagnostics. 14(2). 198–198.
3.
Güller, Ulrich, Stefanie Hayoz, Daniel Horber, et al.. (2024). 512O Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: The phase III, prospective-randomized placebo-controlled multicenter SAKK 41/13 trial. Annals of Oncology. 35. S432–S432.
4.
Kasper‐Virchow, Stefan, Ralf‐Dieter Hofheinz, Sebastian Stintzing, et al.. (2024). LBA25 Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316). Annals of Oncology. 35. S1218–S1218.
5.
Goetze, Thorsten Oliver, Thomas J. Ettrich, Harald Schmalenberg, et al.. (2024). Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial. Oncology Research and Treatment. 47(11). 549–560.
6.
Ettrich, Thomas J., Regine Mayer‐Steinacker, Stephan Stilgenbauer, et al.. (2024). SOP – Darmpassagestörung in der Palliativmedizin.
7.
Heinrich, Kathrin, Volker Heinemann, Sebastian Stintzing, et al.. (2024). Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114). Oncology Research and Treatment. 47(6). 251–261.
8.
Schmidt, Stefan, Wolfgang Thaiss, Thomas J. Ettrich, et al.. (2023). Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging. Diagnostics. 13(17). 2741–2741.
9.
Lorenzen, Sylvie, Peter Thuss‐Patience, Claudia Pauligk, et al.. (2022). FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. European Journal of Cancer. 165. 48–57.
10.
Kraus, Johann M., Thomas J. Ettrich, Hans A. Kestler, et al.. (2022). Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients. Cancers. 14(4). 1074–1074.
11.
Ettrich, Thomas J., et al.. (2022). Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. Visceral Medicine. 38(1). 20–29.
12.
Hüttner, Felix J., et al.. (2022). Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions. Cancers. 14(22). 5580–5580.
13.
Vogel, Arndt, Anna Saborowski, Thomas J. Ettrich, et al.. (2021). LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC). Annals of Oncology. 32. S1312–S1312.
14.
Seufferlein, Thomas, Waldemar Uhl, Hana Algül, et al.. (2021). LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study. Annals of Oncology. 32. S1333–S1333.
15.
Haag, Georg Martin, Sylvie Lorenzen, Thomas J. Ettrich, et al.. (2020). 1447P S-1 maintenance therapy in non-Asian patients with advanced, Her-2 negative esophagogastric adenocarcinoma – First results of the international MATEO trial initiated by the AIO. Annals of Oncology. 31. S910–S910.
16.
Pauligk, Claudia, Peter Thuss‐Patience, Jorge Riera‐Knorrenschild, et al.. (2020). 1443P Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO. Annals of Oncology. 31. S908–S908.
17.
Al-Batran, S-E., Thomas J. Ettrich, K Borchert, et al.. (2020). 1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma. Annals of Oncology. 31. S899–S899.
18.
Gaiser, Maria Rita, Sylvie Lorenzen, Kirsten Merx, et al.. (2019). Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score. Cancer Medicine. 8(9). 4169–4175.
19.
Türeci, Ö., Uğur Şahin, Henning Schulze‐Bergkamen, et al.. (2019). A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Annals of Oncology. 30(9). 1487–1495.
20.
Ettrich, Thomas J., Anke Reinacher‐Schick, Hana Algül, et al.. (2018). A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma. Annals of Oncology. 29. viii663–viii663.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mitsukuni Suenaga Breakdown of academic impact, for papers by Roger Faroux Breakdown of academic impact, for papers by Petra Ruemmele Breakdown of academic impact, for papers by Tsuyoshi Hayashi Breakdown of academic impact, for papers by Nobuhisa Matsuhashi Breakdown of academic impact, for papers by Kazuhito Sasaki Breakdown of academic impact, for papers by Yu Sunakawa Breakdown of academic impact, for papers by Yasuo Ohkura Breakdown of academic impact, for papers by Chueh‐Chuan Yen Breakdown of academic impact, for papers by Kuk Jin Choe